RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179193 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Federico Monti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy. Hauptthemen laut MEDLINE: Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Fatty Liver. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD)—and its worse form, metabolic-associated steatohepatitis (MASH), characterised by inflammation and liver damage—corresponds to the liver’s involvement in metabolic syndrome, which constitutes an economic burden for healthcare systems. However, the biomolecular pathways that contribute to steatotic liver disease are not completely clear. Abnormalities of bone metabolism are frequent in people affected by metabolic liver disease, with reduced bone density and an increased risk of fracture. Receptor activator of NF-κB (RANK), receptor activator of NF-κB ligand (RANKL), and osteoprotegerin(OPG) are critical regulators of bone metabolism, performing pleiotropic effects, and may have potential involvement in metabolic disorders like MASLD, resulting in a topic of great interest and intrigue. This narrative review aims to investigate this potential role and its implications in MASLD development and progression and in hepatocellular carcinoma, which represents its worst complication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Department of Dietetics and Clinical Nutrition, Maggiore-Bellaria Hospital, Azienda Unità Sanitaria Locale (AUSL), 40138 Bologna, Italy.
- Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Division of Endocrinology and Diabetes Prevention and Care, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
- Unit of Clinical Nutrition and Metabolism, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
ORCID-Profile: Federica Perazza, Francesco Tovoli, Guido Zavatta, Fabio Piscaglia, Maria Letizia Petroni, Federico Ravaioli
Zitieren
APA
Monti, F., Perazza, F., Leoni, L., Stefanini, B., Ferri, S., Tovoli, F., Zavatta, G., Piscaglia, F., Petroni, M. L., & Ravaioli, F. (2024). RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179193
Vancouver
Monti F, Perazza F, Leoni L, Stefanini B, Ferri S, Tovoli F, et al. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179193
BibTeX
@article{Monti2024,
author = {Monti, Federico and Perazza, Federica and Leoni, Laura and Stefanini, Bernardo and Ferri, Silvia and Tovoli, Francesco and Zavatta, Guido and Piscaglia, Fabio and Petroni, Maria Letizia and Ravaioli, Federico},
title = {RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179193}
}
EUVIMED